21
Participants
Start Date
August 31, 2014
Primary Completion Date
May 31, 2015
Study Completion Date
December 31, 2015
Rotigotine
Rotigotine is FDA approved for the treatment of Restless Legs Syndrome at doses of 1 mg/24h, 2 mg/24h, and 3 mg/24h. The prescribed dose of rotigotine may be achieved using single or multiple patches. Subjects will titrate the dose based on discussions with the investigator.
Massachusetts General Hospital, Boston
Collaborators (1)
UCB Pharma
INDUSTRY
John Winkelman, MD, PhD
OTHER